Send to

Choose Destination
J Immunother Cancer. 2015 Mar 24;3:10. doi: 10.1186/s40425-015-0054-4. eCollection 2015.

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant.

Author information

Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA.


Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.


Allogeneic transplant; CTLA-4 antigen; Graft vs host disease; Immunotherapy; Interleukin-2; Ipilimumab; Melanoma; Programmed cell death 1 receptor and immune-related adverse events

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center